Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD27 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD27 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD27 Products |
| Gene Delivery | CD27 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD27 Products |
| Benchmark Ab | Anti-CD27 (Sequence of Varlilumab) Recombinant positive control. |
View CD27 Products |
| Validator | CD27 siRNA Set For knockdown verification. |
View CD27 Products |
| Related Target A | CD70 The natural ligand of CD27; crucial for blocking assays and validating CD27-CD70 pathway disruption. |
View CD70 Products |
| Related Target B | OX40 Synergistic co-stimulatory TNFRSF member; frequently screened alongside CD27 for combination immunotherapy. |
View OX40 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Agonistic Activity & Receptor Cross-linking | HEK293-expressed CD27 recombinant proteins preserve native dimeric conformation. Lentiviral vectors enable high-expression stable cell lines for functional reporter assays. |
| Cross-species Cynomolgus/Mouse Evaluation | Human, Cynomolgus, and Mouse CD27 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) based on Varlilumab sequence included for direct comparative assays. |
| False Positives | Validated siRNA pools included for target-specific knockdown verification in primary immune cells. |
Live CD27 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD27 therapeutics is intensifying, with major players shifting focus from traditional monospecific agonist antibodies to bispecific/multispecific antibodies and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the CD27-CD70 axis for hematological malignancies and developing co-stimulatory bispecifics to overcome the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | Celldex Therapeutics | Solid Tumors, Lymphoma | FcγR-mediated cross-linking functional assay (Need high-purity CD27 ECD-Fc & stable cell lines) |
| Bispecific Antibodies | Various Biotechs | Solid Tumors, Hematology | Dual-binding and bridging assays (Need highly stable CD27 recombinant proteins) |
| CAR-T / CAR-NK | Academic Institutions | CD27+ Hematological Malignancies | Target cell killing assays (Need CD27 lentiviral particles for target cell line construction) |